Trade-Ideas: Synageva BioPharma (GEVA) Is Today's Unusual Social Activity Stock

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified Synageva BioPharma ( GEVA) as an unusual social activity candidate. In addition to specific proprietary factors, Trade-Ideas identified Synageva BioPharma as such a stock due to the following factors:

  • GEVA has more that 20x the normal benchmarked social activity for this time of the day compared to its average of 9.65 mentions/day.
  • GEVA has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $417.1 million.

Identifying stocks with 'Unusual Social Activity' tends to be a valuable process for traders looking to capitalize on the 'talk of the town' stocks that are basking in far more attention from the StockTwits financial community than normal. Good press? Bad press? It ultimately doesn't matter if it's good or bad if you know how to trade around the sentiment. Certain hedge funds use such data for their proprietary algorithms and it is not uncommon to see shared social sentiment play itself out in a stock's price trend.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in GEVA with the Ticky from Trade-Ideas. See the FREE profile for GEVA NOW at Trade-Ideas

More details on GEVA:

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases.

The average volume for Synageva BioPharma has been 261,700 shares per day over the past 30 days. Synageva BioPharma has a market cap of $3.0 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.14 and a short float of 25.7% with 2.17 days to cover.

If you liked this article you might like

The Nominees for Best Biopharma CEO of 2015 Are...

Bluebird, Pacira Pharmaceuticals Excite Life Science Investors

Bluebird, Pacira Pharmaceuticals Gain Steam in Burgeoning Life Science Space

New Lifetime High Today: Synageva BioPharma (GEVA)

Where the Money Was Made the Last 5 Years

Where the Money Was Made the Last 5 Years